Month: September 2026

GIG HARBOR, Wash., Sept. 10, 2026 (GLOBE NEWSWIRE) — The Washington Utilities and Transportation Commission (WUTC) has issued a decision in Washington Water Service’s (Washington Water) application to adjust rates and recover costs for investments made to keep its East Pierce and Legacy water systems safe and reliable. The decision, which adopted the all-party settlement reached among Washington Water, WUTC staff, and the Public Counsel Unit of the Washington Attorney General’s Office, enables the California Water Service Group (Group) subsidiary to increase annual revenue by $4.1 million.

Washington Water made $26.5 million in improvements to its water systems from 2023 through 2024, the years covered in the application, to enhance service for its customers and local communities. Some of the major improvements included:

• Installing 1,000 feet of new water main in the Minterbrook system; 700 feet in Sunshine Acres; 2,500 feet in the Ranch Acres Shores system; 2,000 feet in Cedar Grove; 1,000 feet in Evergreen Shores; and 7,000 feet in the Southwood system to improve reliability and fire protection, and reduce potential leaks.
• Installing new treatment facilities to reduce lead and copper in the Heritage Row system, arsenic in the Quistorff system, and iron and manganese in the Southwood system.
• Upgrading booster pump stations in the Rosario, Cedar Crest, Artondale, Southwood, Olympic Mall, and Driftwood Valley systems.
• Deploying Supervisory Control and Data Acquisition remote system monitoring in the Sunshine Acres, Rosario, Mirrormont, Palmer Lake, and Southwood systems.
• Installing a new booster pumping facility to increase reliability and capacity in the Lost Creek zone of the Southwood system.
• Testing, constructing facilities, and treating for certain per- and polyfluoroalkyl substances (PFAS) in accordance with new water quality regulations.

“Protecting the health and safety of our customers is our highest priority, and improvements such as these help us provide high-quality, reliable drinking water for our customers,” said Martin A. Kropelnicki, Group Chairman and CEO. “We appreciate the WUTC enabling us to recover costs needed to keep delivering the quality, service, and value our communities deserve.”

Washington Water expects new rates to become effective in October 2026.

About California Water Service Group

California Water Service Group (NYSE: CWT) is the largest regulated water utility in the western United States. It provides high-quality, reliable water and/or wastewater services to more than 2.2 million people in California, Hawaii, New Mexico, Washington, and Texas through its regulated subsidiaries, California Water Service, Hawaii Water Service, New Mexico Water Service, and Washington Water Service, and its utility holding company, TWSC, Inc. (Texas Water Service). This year, the company commemorates a century of service.

Group’s purpose is to enhance the quality of life for customers, communities, employees, and stockholders. To do so, it invests responsibly in water and wastewater infrastructure, sustainability initiatives, and community well-being. The company’s nearly 1,300 employees live by a set of strong core values and share a commitment to protecting the planet, caring for people, and operating with the utmost integrity. The company has been named one of “America’s Most Responsible Companies” and the “World’s Most Trustworthy Companies” by Newsweek, a USA Top Workplace, and a Great Place to Work^®. More information is available at www.calwatergroup.com.

This news release contains forward-looking statements within the meaning established by the Private Securities Litigation Reform Act of 1995 (PSLRA). The forward-looking statements are intended to qualify under provisions of the federal securities laws for “safe harbor” treatment established by the PSLRA. Forward-looking statements in this news release are based on currently available information, expectations, estimates, assumptions and projections, and our management’s beliefs, assumptions, judgments and expectations about us, the water utility industry and general economic conditions. These statements are not statements of historical fact. When used in our documents, statements that are not historical in nature, including words like will, would, expects, intends, plans, believes, may, could, estimates, assumes, anticipates, projects, progress, predicts, hopes, targets, forecasts, should, seeks or variations of these words or similar expressions are intended to identify forward-looking statements. Examples of forward-looking statements in this news release include, but are not limited to, statements describing the potential timing for the increase in Washington Water’s rates to become effective and plans for related cash receipts. Forward-looking statements are not guarantees of future performance. They are based on numerous assumptions that we believe are reasonable, but they are open to a wide range of uncertainties and business risks. Consequently, actual results or outcomes may vary materially from what is contained in a forward-looking statement. Factors that may cause actual results or outcomes to be different than those expected or anticipated include, but are not limited to those described under the section entitled “Risk Factors” and elsewhere in our most recent Annual Report on Form 10-K, our subsequent Quarterly Reports on Form 10-Q and our other Securities and Exchange Commission filings. In light of these risks, uncertainties and assumptions, investors are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this news release. We are not under any obligation, and we expressly disclaim any obligation to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.

MEDIA CONTACT: Yvonne Kingman, (310) 257-1434

Shares Expected to Begin Trading on a Split-Adjusted Basis on September 14, 2026

MONROE TOWNSHIP, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (“OPT” or the “Company”) (NYSE American: OPTT), a leader in maritime operational infrastructure and autonomous ocean systems, today announced a 1-for-30 reverse stock split (“Reverse Split”) of the Company’s common stock (“Common Stock”). The Common Stock will begin trading on a split-adjusted basis on the NYSE American commencing at the market open on September 14, 2026. The Reverse Split is being effected in order to increase the price per share of the Common Stock to, among other things, improve its marketability and liquidity. The new CUSIP number for the Common Stock following the Reverse Split will be 674870 605.

As a result of the Reverse Split, each 30 shares of the issued and outstanding Common Stock will be automatically combined and converted into one issued and outstanding share of Common Stock. No fractional shares will be issued as a result of the Reverse Split. Stockholders who otherwise would be entitled to a fractional share will automatically be entitled to receive one whole share of Common Stock for each such fractional share.

Each shareholder’s pro-rata percentage ownership will remain unchanged as a result of the Reverse Split and no further action is required by stockholders. All of the Company’s current outstanding warrants to purchase shares of Common Stock and other derivatives automatically adjust per their terms to reflect the Reverse Split. Immediately after the Reverse Split becomes effective, there will be approximately 9.1 million shares of Common Stock issued and outstanding.

In connection with the Reverse Stock Split, an automatic, mechanical, and proportional adjustment was made to the purchase price of the preferred stock purchase rights (the “Rights”) issued pursuant to the Company’s Amended and Restated Section 382 Tax Benefits Preservation Plan, dated as of June 29, 2026 (the “Plan”), by and between the Company and Computershare Trust Company, N.A., as rights agent, pursuant to Section 11(o) thereof.

Effective as of the effective time of the Reverse Stock Split, the initial purchase price of $2.25 per one thousandth of a share of Series A Participating Preferred Stock was multiplied by the Reverse Stock Split ratio factor of 30, resulting in an adjusted purchase price of $67.50 per one one-thousandth of a share of Preferred Stock, subject to further adjustment as provided in the Rights Plan.

Pursuant to Section 11(o) of the Plan, the fraction of a share of Preferred Stock purchasable upon exercise of each Right remains unchanged at one one-thousandth of a share, and the number of Rights associated with each outstanding share of Common Stock remains unchanged at one (1) Right per share.

The Reverse Stock Split did not cause any stockholder or any affiliate or associate thereof to become an “Acquiring Person” under the Plan. Nor did the Reverse Stock Split cause the occurrence of a “Distribution Time,” “Stock Acquisition Date,” or other “Triggering Event” under the Plan.

For further details, all stockholders are invited to review the Current Report on Form 8-K regarding the Reverse Stock Split which will be filed September 11, 2026.

For more information about Ocean Power Technologies, visit www.OceanPowerTechnologies.com.

ABOUT OCEAN POWER TECHNOLOGIES

OPT provides intelligent maritime solutions and services that enable safer, cleaner, and more productive ocean operations for the defense and security, oil and gas, science and research, and offshore wind markets, including Merrows™, which provides AI capable seamless integration of Maritime Domain Awareness Systems across platforms. Our PowerBuoy® platforms provide clean and reliable electric power and real-time data communications for remote maritime and subsea applications. We also provide WAM-V® unmanned surface vessels (USVs) and marine robotics services. The Company’s headquarters is in Monroe Township, New Jersey, with an additional office in Richmond, California. To learn more about OPT’s products, services and solutions, visit www.OceanPowerTechnologies.com.

FORWARD-LOOKING STATEMENTS

This release may contain forward-looking statements that are within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are identified by certain words or phrases such as “may”, “will”, “aim”, “will likely result”, “believe”, “expect”, “will continue”, “anticipate”, “estimate”, “intend”, “plan”, “contemplate”, “seek to”, “future”, “objective”, “goal”, “project”, “should”, “will pursue” and similar expressions or variations of such expressions. These forward-looking statements reflect the Company’s current expectations about its future plans and performance. These forward-looking statements rely on a number of assumptions and estimates that could be inaccurate and subject to risks and uncertainties, including the Company’s ability to have a successful Reverse Stock Split, the delivery of customer services, the conversion of potential customers to contracts and the realization of the potential revenue thereunder. Actual results could vary materially from those anticipated or expressed in any forward-looking statement made by the Company. Please refer to the Company’s most recent Forms 10-Q and 10-K and subsequent filings with the U.S. Securities and Exchange Commission for further discussion of these risks and uncertainties. The Company disclaims any obligation or intent to update the forward-looking statements in order to reflect events or circumstances after the date of this release.

Contact Information

Investors: 203-561-6945 or investorrelations@oceanpowertech.com

Media: 609-730-0400 x402 or MediaRelations@oceanpowertech.com

Strategic Partnership Positions Flyte at the Intersection of Private Aviation, Fashion, and Entertainment Collaboration Introduces Flyte to a High-Value Audience of Celebrities, Executives, Creators and Cultural Tastemakers

New York Fashion Week Partnership Advances Flyte’s Strategy to Build a Leading Private Aviation Brand Around Premier Destinations, Events and Experiences

FORT MILL, S.C., Sept. 10, 2026 (GLOBE NEWSWIRE) — Flyte, a subsidiary of Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”), today announced a strategic partnership with acclaimed New York fashion designer Christian Cowan in connection with New York Fashion Week, bringing together private aviation and fashion during one of the world’s most influential cultural events. 
The partnership places Flyte alongside Christian Cowan during New York Fashion Week and represents another significant step in the Company’s strategy to build Flyte into a recognizable consumer brand at the intersection of private aviation, entertainment, fashion, sports, hospitality and luxury lifestyle.
Christian Cowan has built an internationally recognized fashion brand known for bold, high-energy designs and a global celebrity following. Through the partnership, Flyte will align its growing private aviation platform with the Christian Cowan brand and the influential audience surrounding New York Fashion Week.

“New York Fashion Week is one of the most influential cultural stages in the world, and Christian Cowan has built a brand that is bold, modern and instantly recognizable,” said Marc Sellouk, Founder and CEO of Flyte. “This partnership represents exactly where we want Flyte to be. Our customers live at the intersection of business, fashion, entertainment, sports and travel, and our strategy is to build Flyte directly into that lifestyle. We believe partnerships like this allow us to introduce private aviation to new audiences while continuing to build Flyte into a brand that extends far beyond the aircraft itself.”

Private Aviation Meets New York Fashion Week
New York Fashion Week brings together leading designers, celebrities, creators, executives, media and tastemakers from around the world, providing Flyte with an opportunity to engage an audience that closely aligns with the Company’s target customer demographic.

For Flyte, the partnership represents more than traditional brand exposure. The Company has increasingly focused its marketing strategy on creating direct relationships with consumers through strategic partnerships, digital marketing, influencer initiatives, experiential activations and its technology-enabled booking platform.

The Christian Cowan partnership extends that strategy into the global fashion community.
Flyte believes integrating its brand into culturally relevant events and experiences can introduce the Company to prospective private aviation customers in an environment that is authentic to their existing lifestyles, rather than relying exclusively on traditional private aviation marketing channels.

Building Flyte Into a Lifestyle Brand
Flyte is building a growing private aviation platform around a standardized fleet of Cirrus Vision Jets, a direct-to-consumer technology platform and an expanding network of strategic partnerships.

As the Company expands, Flyte has increasingly aligned itself with leading organizations and brands across hospitality, entertainment, professional sports, golf, film, fashion and luxury lifestyle. Management believes these relationships create opportunities to simultaneously increase brand awareness, acquire new customers and establish Flyte within communities that have a strong demographic overlap with private aviation travelers.

“Our goal is not simply to market private flights,” Sellouk continued. “We are building a brand around how our customers actually live and travel. Whether they are going to a major sporting event, a film festival, a luxury resort or New York Fashion Week, we want Flyte to become part of that experience. Christian Cowan and New York Fashion Week give us an incredible opportunity to continue that strategy on a global cultural stage.”

Flyte’s technology platform provides the infrastructure behind this strategy, giving consumers introduced to Flyte through partnerships and experiential marketing a direct path to engage with the Company, create an account and access its private aviation network.

The Company believes this combination of physical aircraft, technology and culturally relevant partnerships can differentiate Flyte within a private aviation industry that has historically relied heavily on traditional sales and relationship-based customer acquisition.

Expanding Flyte’s Presence Across Culture and Luxury Travel
The Christian Cowan partnership comes as Flyte continues expanding its fleet, geographic footprint, digital platform and strategic partnership network.

The Company intends to continue pursuing partnerships across fashion, entertainment, hospitality, sports and other premium lifestyle categories as it works to establish Flyte as a recognizable consumer brand within private aviation.

Flyte believes these relationships can become an increasingly important component of its long-term customer acquisition strategy as the Company scales into additional markets.

About Christian Cowan
Christian Cowan is a New York-based fashion designer known for bold, statement-making collections and a strong presence within fashion and popular culture. His designs have been worn by prominent figures across music, entertainment and culture, establishing the Christian Cowan brand as a distinctive presence within contemporary fashion.

About Flyte
Flyte is a modern private aviation brand redefining regional travel for a new generation of private flyers. Powered by a growing fleet of Cirrus Vision Jets and a seamless, direct-to-consumer booking experience, Flyte connects New York, Boston, the Hamptons, Nantucket and destinations across the United States and select international markets. By pairing the privacy and luxury of private aviation with innovative technology, exceptional service and a model built for shorter-distance travel, Flyte is making the places people want to be closer than ever.

Visit https://www.flyflyte.com to fly & learn more.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable federal securities laws. Forward-looking statements include statements regarding Flyte’s anticipated growth, customer acquisition, brand development, strategic partnerships, geographic expansion, fleet expansion and the potential commercial impact of its marketing and partnership strategies. These statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Readers are encouraged to review the Company’s filings with the Securities and Exchange Commission, including its Forms 10-K and 10-Q, for additional information regarding these risks.

Contacts
Investor Relations
IR@CatheterPrecision.com
973-691-2000

ATHENS, Greece, Sept. 10, 2026 (GLOBE NEWSWIRE) — Global Ship Lease, Inc. (NYSE:GSL) (the “Company”), a containership owner and lessor, announced today that the Company’s Board of Directors has declared a cash dividend of $0.546875 per depositary share, each representing a 1/100th interest in a share of its 8.75% Series B Cumulative Redeemable Perpetual Preferred Shares (the “Series B Preferred Shares”) (NYSE:GSLPrB). The dividend represents payment for the period from July 1, 2026 to September 30, 2026 and will be paid on October 1, 2026 to all Series B Preferred Shareholders of record as of September 24, 2026.

About Global Ship Lease

Global Ship Lease is a leading independent owner of containerships with a diversified fleet of mid-sized and smaller containerships. Incorporated in the Marshall Islands, Global Ship Lease commenced operations in December 2007 with a business of owning and chartering out containerships under fixed-rate charters to top tier container liner companies. It was listed on the New York Stock Exchange in August 2008.

Our operating fleet of 71 containerships as of June 30, 2026, had an average age weighted by TEU capacity of 18.4 years. 41 ships are wide-beam Post-Panamax. As of June 30, 2026, our fleet also included 15 newbuilding containerships under construction with scheduled deliveries between the fourth quarter of 2028 and the first quarter of 2030.

As of June 30, 2026, the average remaining term of the Company’s charters, to the mid-point of redelivery, including options under the Company’s control and other than if a redelivery notice has been received, including our newbuildings, was 3.3 years on a TEU-weighted basis. Contracted revenue, including our newbuildings, on the same basis was $3.2 billion. Contracted revenue was $4.1 billion, including options under charterers’ control and with latest redelivery date, representing a weighted average remaining term of 4.4 years.

Forward-Looking Statements

This press release contains forward-looking statements. Forward-looking statements provide the Company’s current expectations or forecasts of future events. Forward-looking statements include statements about the Company’s expectations, beliefs, plans, objectives, intentions, assumptions and other statements that are not historical facts. Words or phrases such as “anticipate,” “believe,” “continue,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “will” or similar words or phrases, or the negatives of those words or phrases, may identify forward-looking statements, but the absence of these words does not necessarily mean that a statement is not forward-looking. These forward-looking statements are based on assumptions that may be incorrect, and the Company cannot assure you that the events or expectations included in these forward-looking statements will come to pass. Actual results could differ materially from those expressed or implied by the forward-looking statements as a result of various factors, including the factors described in “Risk Factors” in the Company’s Annual Report on Form 20-F and the factors and risks the Company describes in subsequent reports filed from time to time with the U.S. Securities and Exchange Commission. Accordingly, you should not unduly rely on these forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly revise any forward-looking statement to reflect circumstances or events after the date of this press release or to reflect the occurrence of unanticipated events.

Investor and Media Contact:
IGB Group
Bryan Degnan
646-673-9701
or
Leon Berman
212-477-8438

ATLANTA, Sept. 10, 2026 (GLOBE NEWSWIRE) — Atlanticus Holdings Corporation (NASDAQ: ATLC) (“Atlanticus,” the “Company,” “we,” “our” or “us”), a financial technology company that enables its bank, retail and healthcare partners to offer more inclusive financial services to millions of everyday Americans, today announced that Jeff Howard, President and Chief Executive Officer, and Bill McCamey, Chief Financial Officer, will participate in the U.S. Bancorp | BTIG Consumer Finance Conference 2026 in Boston, MA on September 17, 2026.

Information regarding the conference will also be available in the Events and Presentations section of the Company’s Investor Relations website at https://investors.atlanticus.com.

About Atlanticus Holdings Corporation

Empowering Better Financial Outcomes for Everyday Americans

Atlanticus Holdings Corporation empowers better financial outcomes for Everyday Americans by enabling bank, retail, healthcare, and automotive partners to offer more inclusive financial solutions to consumers. Leveraging proprietary technology and advanced analytics, Atlanticus applies more than 30 years of operating experience, servicing over 23 million customers and more than $53 billion in consumer loans, to support lenders across a broad range of consumer credit products. These offerings span retail and healthcare private-label credit and general purpose credit cards, through an omnichannel platform, including strategic partnerships. Additionally, through its Auto Finance subsidiary, Atlanticus helps address the specific needs of automotive dealerships and non-prime automotive finance organizations with a range of financing and service programs.

Atlanticus is guided by the principles of responsible lending, smart innovation, and expanding access to credit for consumers working toward a stronger financial future.

Contact:
Investor Relations, investors@atlanticus.com
Dan Mauch, daniel.mauch@atlanticus.com
Sara Savarino, sara.savarino@atlanticus.com

HARTFORD, Conn. and BOSTON, Sept. 10, 2026 (GLOBE NEWSWIRE) — The Board of Trustees of Eversource Energy (NYSE:ES) today approved a quarterly dividend of $0.7875 per share, payable on September 30, 2026, to shareholders of record as of the close of business on September 21, 2026.

Eversource (NYSE: ES), celebrated as a national leader for its commitment to sustainability and corporate citizenship, is named among America’s Most Responsible Companies by Newsweek for 2026 and recognized as the #1 utility on USA Today’s list of America’s Climate Leaders for 2025. Eversource transmits and delivers electricity and natural gas to approximately 4 million customers in Connecticut, Massachusetts and New Hampshire. The #1 Energy Efficiency Provider in the Nation, Eversource harnesses the commitment of more than 10,500 employees across three states to build a single, united company around the mission of safely delivering reliable energy and water with superior customer service. The company is empowering a clean energy future in the Northeast, with nationally recognized energy efficiency solutions and successful programs to integrate new clean energy resources like a first-in-the-nation networked geothermal pilot project, solar, offshore wind, electric vehicles and battery storage, into the electric system. For more information, please visit eversource.com, and follow us on X, Facebook, Instagram, and LinkedIn.

CONTACT:
Rima Hyder (Investor Relations)
781-441-8882
rima.hyder@eversource.com

William Hinkle (Media Relations)
william.hinkle@eversource.com
(603) 634-2228

GROSSE POINTE FARMS, Mich., Sept. 10, 2026 (GLOBE NEWSWIRE) — Saga Communications, Inc. (Nasdaq – SGA) (the “Company”, “Saga” or “our”) today announced that its Board of Directors (“Board”) declared a quarterly cash dividend of $0.25 per share. The dividend will be paid on October 16, 2026, to shareholders of record on September 23, 2026. The aggregate amount of the payment to be made in connection with the quarterly dividend will be approximately $1.6 million. The quarterly dividend will be funded by cash on the Company’s balance sheet. Including this dividend, the Company will have paid over $146 million in dividends to shareholders since the first special dividend was paid in 2012.

The Company currently intends to declare regular quarterly cash dividends in the future. The declaration and payment of any future dividend, whether fixed, special, or based on the variable policy, or the implementation of any stock buyback program will remain at the full discretion of the Board and will depend on the Company’s financial results, cash requirements, future expectations, and other pertinent factors.

Saga is a media company whose business is devoted to acquiring, developing and operating broadcast properties with a focus on providing opportunities complimentary to our core radio business including digital, e-commerce, local on-line news services and non-traditional revenue initiatives. Saga owns or operates broadcast properties in 28 markets, including 82 FM and 28 AM radio stations and 78 metro signals. For additional information, contact us at (313) 886-7070 or visit our website at www.sagacom.com.

This press release contains certain forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 that are based upon current expectations and involve certain risks and uncertainties. Words such as “will,” “may,” “believes,” “intends,” “expects,” “anticipates,” “guidance,” and similar expressions are intended to identify forward-looking statements. The material risks facing our business are described in the reports Saga periodically files with the U.S. Securities and Exchange Commission, including, in particular, Item 1A of our Annual Report on Form 10-K. Readers should note that forward-looking statements may be impacted by several factors, including global, national, and local economic changes and changes in the radio broadcast industry in general as well as Saga’s actual performance. Actual results may vary materially from those described herein and Saga undertakes no obligation to update any information contained herein that constitutes a forward-looking statement.

Contact:
Samuel D. Bush
(313) 886-7070

TULSA, Okla., Sept. 10, 2026 (GLOBE NEWSWIRE) — ONEOK, Inc. (NYSE: OKE) today announced the closing of the previously announced $9 billion minority equity investment by funds and affiliates managed by Apollo (NYSE: APO) (Apollo). 

Under the terms of the agreement, Apollo has invested $9 billion in exchange for a nonvoting Class B minority interest in a newly formed holding company, ONEOK Holdings, L.L.C., which is structurally subordinate to the company’s debt.

The minority equity investment has been reviewed with ONEOK’s credit rating agencies, all of which consider the transaction credit-enhancing.

—————————————————————————————————————-
ABOUT ONEOK:

At ONEOK (NYSE: OKE), we deliver energy products and services vital to an advancing world. We are a leading midstream operator that provides gathering, processing, fractionation, transportation, storage and marine export services. Through our approximately 60,000-mile pipeline network, we transport the natural gas, natural gas liquids (NGLs), refined products and crude oil that help meet domestic and international energy demand, contribute to energy security and provide safe, reliable and responsible energy solutions needed today and into the future. As one of the largest integrated energy infrastructure companies in North America, ONEOK is delivering energy that makes a difference in the lives of people in the U.S. and around the world.

ONEOK is an S&P 500 company headquartered in Tulsa, Oklahoma.

For information about ONEOK, visit www.oneok.com. For the latest news, visit the ONEOK newsroom or find us on LinkedIn, Facebook, X and Instagram.

ABOUT APOLLO:

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of June 30, 2026, Apollo had approximately $1.05 trillion of assets under management. To learn more, please visit www.apollo.com.

FORWARD-LOOKING STATEMENTS:

Some of the statements contained and incorporated in this news release are forward-looking statements as defined under federal securities laws. The forward-looking statements relate to our anticipated financial performance (including projected levels of quarterly and annual dividends and adjusted EBITDA), growth, leverage, synergies, liquidity, market conditions and other matters. We make these forward-looking statements in reliance on the safe harbor protections provided under federal securities laws and other applicable laws.

Forward-looking statements include the items identified in the preceding paragraph, the information concerning possible or assumed future results of our operations and other statements contained or incorporated in this news release identified by words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “guidance,” “intend,” “may,” “might,” “outlook,” “plan,” “potential,” “project,” “scheduled,” “should,” “will,” “would” and other words and terms of similar meaning.

One should not place undue reliance on forward-looking statements. Known and unknown risks, uncertainties and other factors may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by forward-looking statements. Those factors may affect our operations, markets, products, services and prices. These and other risks are described in greater detail in Item 1A, Risk Factors, in our most recent Annual Report on Form 10-K and in the other filings that we make with the Securities and Exchange Commission (SEC), which are available on the SEC’s website at www.sec.gov. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these factors. Any such forward-looking statement speaks only as of the date on which such statement is made, and, other than as required under securities laws, we undertake no obligation to update publicly any forward-looking statement whether as a result of new information, subsequent events or change in circumstances, expectations or otherwise.

Contacts:

Investor Relations:
Megan Patterson
918-561-5325
ONEOKInvestorRelations@oneok.com

Media Relations:
Alicia Keenom
918-861-3749
Media@oneok.com

Transaction Includes a Turnkey Prepaid Wireless Company and the Managed Marketing Services Platform

BARTLETT, Tenn., Sept. 10, 2026 (GLOBE NEWSWIRE) — SurgePays, Inc. (NASDAQ: SURG), a fintech and wireless company, today announced that it has completed the sale of its ClearLine point of sale (POS) engagement platform, its Managed Marketing Services platform, and a turnkey wireless company (MVNO), together with related operating assets, to GPO Plus, Inc. (“GPO Plus”) for a total consideration of $27.5 million.

ClearLine is an innovative point of sale digital marketing platform that turns credit card payment terminals and customer facing screens into a dynamic, interactive marketing channel for retailers. The software delivers a seamless approach to marketing campaigns designed to increase customer spending, capture reviews and feedback, gather customer data, and digitize loyalty program enrollment through hyperlocal marketing on payment terminals and POS screens.

ClearLine’s platform includes reviews, deals, surveys, VIP club, gift cards, coupons, birthday club, loyalty, referral program, Wi Fi marketing, geofencing, push messages, POS system integration, and NFC tags, giving merchants a single dashboard to run engagement and marketing across the storefront and the point of sale. The platform is backed by U.S. Patent No. 12,632,881 B2, which covers its merchant engagement technology.

The transaction also includes the proprietary Managed Marketing Services (MMS) platform. The ClearLine managed digital marketing network turns smart TVs installed in retail locations into a dynamic, remotely controlled media channel in place of traditional printed signage. Video commercials, static ads, QR code or coupon offers, and more can be controlled not only at the store level, but down to the TV if multiple TVs are placed in different areas of the store. The MMS platform can generate advertising revenue and promote products and services to the captive in-store audience.

The turnkey prepaid wireless company was built using SurgePays’ existing platforms, carrier contracts, and integrated software infrastructure.

For SurgePays, the transaction sharpens the Company’s focus on its core prepaid wireless and fintech businesses, monetizes the significant investment in the ClearLine development over the last three years at a meaningful valuation, and materially strengthens the Company’s balance sheet.

As consideration for the transaction, GPO Plus issued to SurgePays 25,000,000 shares of a newly designated Series D Preferred Stock. As part of the transaction, SurgePays also entered into a put option agreement with Emerald Shoals Targeted Opportunities Fund LP (“Emerald Shoals”), giving SurgePays the right to sell the Series D Preferred Stock, or the common stock it converts into, to Emerald Shoals for $27.5 million in cash.

“This is a win-win for both companies and their shareholders,” said Brian Cox, Chief Executive Officer of SurgePays. “On the heels of some remarkable recent MVNO valuations, we are delivering the ClearLine POS engagement platform, the MMS platform, and a turnkey prepaid wireless company to GPO Plus. I am a big fan of GPO’s DSD model, and we believe adding these platforms can drive meaningful new revenue streams across their network. For SurgePays, monetizing ClearLine and the turnkey MVNO strengthens our balance sheet and lets us put our full focus on our core prepaid wireless and fintech businesses.”

Additional information regarding the transaction, including the Asset Purchase Agreement and related agreements, is included in the Current Report on Form 8-K filed by SurgePays with the Securities and Exchange Commission on the date of this release, which may be accessed at www.sec.gov.

About SurgePays

SurgePays, Inc. (NASDAQ: SURG) is a fintech and mobile virtual network operator (MVNO) that delivers prepaid wireless and financial products to the approximately 138 million subprime consumers in the United States. Through its proprietary point of sale platform deployed across approximately 9,000 convenience stores and a growing Retail Media Network, SurgePays enables retailers to offer wireless activations, top ups, and consumer financial services. The Company’s subsidiaries include LinkUp Mobile, Torch Wireless, and the ProgramBenefits.com platform, which is being built to incorporate AI driven decisioning across the financial and benefit products it offers. SurgePays is headquartered in Bartlett, TN. Learn more at www.surgepays.com and ir.surgepays.com.

Forward Looking Statements

This press release contains forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements are based on the Company’s current expectations regarding the transaction described above, the intended benefits of the transaction, and the Company’s ongoing business. Because forward looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside the Company’s control. Actual results and financial condition may differ materially from those indicated in the forward looking statements. Important factors that could cause actual results to differ are discussed in the Company’s filings with the Securities and Exchange Commission, including the risk factors contained in its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q. Readers are cautioned not to place undue reliance on forward looking statements, which speak only as of the date of this release. The Company undertakes no obligation to update these statements, except as required by law.

Investor and Media Contact

MDM Worldwide | Investor Relations
ir@surgepays.com

TORONTO, ONTARIO, Sept. 10, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the acquisition of Nualtis Corp. (“Nualtis”), a Montreal-based specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies, with applications for both human and animal health. The Company also announced the completion of the first tranche of a non-brokered private placement of unsecured convertible debentures.

ACQUISITION HIGHLIGHTS:

• Strategic acquisition of a leading oral thin film (“OTF”) development and manufacturing platform: Nualtis is an industry leader and innovator in OTF drug delivery technology, adding a purpose-driven team and an FDA- and Health Canada-inspected GMP manufacturing facility in Montreal, Canada.
• Established development and commercial partnerships across a diversified product pipeline: A portfolio of programs spanning human and animal health, protected by 21 foundational patents, with partnerships in place with established pharmaceutical companies.
• Growing cash-flow-positive business model: The Company believes Nualtis is poised for continued, profitable future growth through diverse revenue streams, including research and development (“R&D”) services, manufacturing and supply, milestone payments, and product royalties.

“We are very excited to announce the acquisition of Nualtis. COSCIENS now has direct exposure to the large and growing global OTF market through Nualtis’ leading facility, intellectual property and know-how, and its established product pipeline and partnerships,” said Peter Puccetti, CEO and Chairman of COSCIENS. “Since joining COSCIENS last year, I, and my fellow directors and officers, have been committed to a plan for creating shareholder value. During an initial period of restructuring, we made significant improvements in the Company’s financial health and on achieving financial self-sufficiency of the existing business. In Q2, Ceapro contributed over US$422,000 of income from operations and we believe it will continue to meaningfully contribute to earnings going forward. More recently, we shifted our focus to actively exploring opportunities for growth and scale. We believe this transaction represents exactly that. Nualtis is led by a talented and driven management team and is positioned for significant growth as it transitions from mostly R&D revenue to more commercial-scale manufacturing revenue. We believe that COSCIENS is well-positioned to help guide and support that growth path.”

Michael Raven, CEO of Nualtis since 2024, commented “We have made great improvements to Nualtis’ business strategy and approach over the last couple of years laying the seeds for substantial profitable growth. COSCIENS’ ownership will provide Nualtis with a platform from which to continue what it has started and Nualtis management couldn’t be more excited about the future of the business.”

The Acquisition and the Acquired Business

The acquisition was completed pursuant to a share purchase agreement between the Company and AtaiBeckley Inc. (“AtaiBeckley”) for a cash purchase price of US$15 million, subject to customary adjustments, plus up to four earn-out payments based on a formula specified in the purchase agreement and equal to 10% of the EBITDA of Nualtis (adjusted in accordance with the purchase agreement) for the financial years 2027 through 2030 (subject to certain other adjustments specified in the purchase agreement). At closing, the Company made an initial payment of US$9 million (the “Closing Date Purchase Price”), subject to adjustments, and the remaining US$6 million is due as a deferred payment within six months (the “Deferred Payment”).

Nualtis (formerly IntelGenx Corp.) was established in 2003. It specializes in the development of oral thin film technology and operates as a contract development and manufacturing organization. The global pharmaceutical oral thin film market was estimated at US$3.8 billion in 2024 and is expected to grow significantly over the next few years.¹ In addition, Nualtis offers a broad portfolio of pharmaceutical services, including pharmaceutical R&D, clinical monitoring, regulatory support, analytical testing, licensing, and commercial manufacturing. Nualtis also holds a Health Canada Drug Establishment Licence, in respect of importation, manufacturing, packaging, labeling, and testing. Nualtis typically applies its oral thin film platforms to active pharmaceutical ingredients with a known mechanism of action and an established safety profile, which keeps development timelines and costs low and gives partners a faster and lower-risk path to differentiated products.

Nualtis’ product development is anchored by two proprietary oral thin film platforms: VersaFilm^® for human therapeutics and VetaFilm^® for veterinary applications. Both use a thin, FDA-compliant polymeric film that dissolves quickly in the mouth, offering an alternative to traditional tablets.

Nualtis’ product pipeline is well-diversified, spanning a mix of generic, branded, over-the-counter (“OTC”) and prescription products, in various therapeutic areas and with multiple partners. The product pipeline also represents various stages of product development, spanning from early-stage R&D to products expected to reach commercial launch in the near term. Within the next five years, the Company believes the successful commercialization of products in Nualtis’ existing pipeline could result in tens of millions of dollars in annual revenue.

Set out below is some additional detail on certain programs within the portfolio representing exemplary near- and medium-term opportunities:

Human Health / Migraine

RizaFilm^® (a registered trademark of Nualtis’ partner, Gensco Laboratories LLC (“Gensco”)) is a proprietary prescription oral thin film containing rizatriptan benzoate. RizaFilm is the first and only FDA-approved oral dissolvable film for migraine in the United States, approved for adults (10 mg) in April 2023 and for pediatric patients (5 mg) in February 2026. Gensco Pharma owns the global rights and has announced a U.S. launch in October 2026, with Nualtis as its manufacturer.

The film is placed on the tongue and dissolves rapidly without a drink, allowing patients to treat at the earliest onset of symptoms, and is protected by an issued patent with substantial remaining exclusivity.

Migraine affects more than 42 million Americans and is the second leading cause of disability nationwide.² The global migraine drugs market was approximately US$7.9 billion in 2025 and is projected to reach US$16.6 billion by 2033 (9.2% CAGR).³

Human Health / Chronic Pain

Nualtis and Chemo Research, S.L., together with its affiliate Xiromed LLC (collectively, “Xiromed”), are developing a generic buprenorphine buccal film that incorporates Nualtis’ VersaFilm^® technology and is intended to be a generic version of Belbuca^®, an opioid delivered as a buccal film and indicated for severe chronic pain. Nualtis is responsible for product development and manufacturing-related activities, while Xiromed is responsible for the regulatory approval and commercialization of the product.

Net revenue of Belbuca^® was $221.7 million for FY2025, up 5% year-over-year⁴ in the U.S. market. No generic versions of Belbuca^® have been launched to date in the United States.

Animal Health

In collaboration with Covenant Animal Health Partners (“Covenant”), Nualtis has developed an undisclosed, proprietary formulation for a veterinary use case in a market that has seen greater than US$100 million in annual sales. Initial clinical studies have shown positive results and received positive feedback from veterinarians.

We look forward to providing further updates regarding the product pipeline and as programs and candidates advance through development, regulatory approval and commercialization.

The Concurrent Financing

To finance the Closing Date Purchase Price, the Company completed the first tranche of a concurrent non-brokered private placement (the “Offering”) of unsecured convertible debentures (the “Debentures”) in an aggregate principal amount of approximately US$6 million. The terms of the Debentures contemplate the issuance of an aggregate principal amount of up to US$20 million, and the Company anticipates closing one or more additional tranches in the coming weeks. Additional subscriptions have already been received by the Company for more than US$4 million and the Company expects to receive further subscriptions in time for an anticipated second tranche closing next week.

“Between COSCIENS’ existing cash resources and the proceeds of the first tranche of Debentures, COSCIENS continues to have excess cash after payment of the Closing Date Purchase Price and accounting for all related payments and transaction expenses. Additional closings of the Debentures for a total of US$20 million would also leave COSCIENS with a material excess cash balance after the second payment to AtaiBeckley in approximately 6 months’ time,” said Giuliano La Fratta, CFO of COSCIENS.

Completion of additional tranches is subject to customary closing conditions, and there can be no assurance that additional tranches will be completed for the anticipated amount or at all.

The Debentures bear an annual interest of 15.0%, payable monthly in arrears, and mature on September 10, 2027 (the “Maturity Date”), and in certain circumstances and subject to shareholder approval, are convertible into common shares of the Company (“Common Shares”) at a price of US$7.00 per Common Share, subject to adjustment (the “Conversion Price”). The Conversion Price is subject to customary anti-dilution provisions and an additional downward adjustment (the “Ratchet”) if the Company completes an equity raise prior to the Maturity Date at an issue price per Common Share that is less than the Conversion Price.

Pursuant to the rules and policies of the Toronto Stock Exchange (the “TSX”), the conversion rights and certain related terms (including the Ratchet) require shareholder approval. Notably, Section 611 of the TSX Company Manual generally requires shareholder approval where the common shares issuable in payment of the purchase price for an acquisition (including in a concurrent private placement upon which the acquisition is contingent or otherwise linked) exceeds 25% of the number of common shares that are outstanding, on a non-diluted basis. As of September 10, 2026, there were 997,219 outstanding Common Shares. If the Debentures issued in today’s closing were converted in full at the Conversion Price, it would result in the issuance of approximately 850,000 additional Common Shares (or approximately 85% of the currently outstanding Common Shares). The Company has agreed to call a meeting of shareholders (the “Meeting”) within six months to seek the necessary approvals. Additional details will be provided in a forthcoming management information circular, which, once filed, will be available on SEDAR+ at www.sedarplus.ca.

If all necessary shareholder and TSX approvals (the “Required Approvals”) are obtained, the Company may, in its sole discretion, require the conversion of all or any portion of the aggregate principal amount of Debentures into Common Shares at the Conversion Price. The Company’s conversion right is not conditional on the Common Shares trading above a specified market price or satisfying a minimum trading-volume or liquidity threshold.

Following the Meeting, whether or not the Required Approvals are obtained, the Company will have a right at any time to repay all or any portion of the Debentures in cash, at par, provided that, if the Company seeks to repay the Debentures in cash (whether as an early repayment or at Maturity), each of the holder of Debentures will, subject to receipt of the Required Approvals, first have the option to convert at the Conversion Price. Interest will, in all cases, be paid in cash.

Certain directors and officers (the “related parties”) of the Company are participating in the Offering for an aggregate principal amount of approximately US$1.3 million, and accordingly the Offering is a “related party transaction” within the meaning of Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”). Additional demand from insiders of the Company could not be met, as the Company is relying on the exemptions from the formal valuation and minority shareholder approval requirements of MI 61-101 contained in sections 5.5(a) and 5.7(1)(a) of MI 61-101, on the basis that at the time the Offering was agreed to, neither the fair market value of the Debentures nor the consideration paid therefor, insofar as it involved the related parties, exceeds 25% of the Company’s market capitalization (as determined as at the end of August in accordance with MI 61-101). Additional details will be provided in a forthcoming material change report, which, once filed, will be available on SEDAR+ at www.sedarplus.ca.

In connection with this closing, the Company agreed to pay finders’ fees (a “Finder’s Fee”) on certain subscriptions, which Finder’s Fees may be satisfied in cash or through the issuance of Debentures. Total Finder’s Fees for the closing amounted to US$181,250 aggregate principal amount of Debentures. Any Debentures issued as Finder’s Fees will be counted towards the maximum aggregate principal amount of US$20,000,000.

The Debentures (and Common Shares issuable upon conversion of the Debentures) are subject to a four-month hold period under Canadian securities laws.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described in this news release in the United States. Such securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and, accordingly, may not be offered or sold within the United States, or to or for the account or benefit of persons in the United States or “U.S. Persons”, as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from such registration requirements.

About COSCIENS Biopharma Inc.

COSCIENS Biopharma Inc. is a holding company operating through its subsidiaries, including Ceapro Inc. (“Ceapro”) and Nualtis^TM.

Ceapro is focused on the development and commercialization of natural, plant-based active ingredients derived from oats and other renewable plant resources, using proprietary manufacturing and extraction technologies. Ceapro’s primary active ingredient business activities relate to the development and commercialization of natural products for the personal care, cosmetic, human and animal health industries.

Nualtis is a specialty pharmaceutical technology business focused primarily on proprietary oral thin-film drug delivery technologies. Its business model includes pharmaceutical formulation development, analytical and regulatory support services, contract development and manufacturing activities, partner-sponsored development programs and commercial product manufacturing.

The Company’s common shares are listed on the TSX under the symbol “CSCI” and are listed and posted for trading on the OTCQB^® Venture Market under the symbol “CSCIF”. For more information, please visit COSCIENS’ website at www.cosciensbio.com.

Forward-Looking Statements

Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Specific forward-looking statements in this document include, but are not limited to, statements relating to: the expected benefits of the Nualtis acquisition; the timing and outcome of regulatory submissions, approvals and related commercialization activities for Nualtis’ product pipeline; the growth of the markets in which Nualtis’ product pipeline operates; manufacturing validation, scale-up and commercialization readiness for Nualtis’ product pipeline; the anticipated revenue and other potential economic contributions associated with Nualtis’ product pipeline; the timing, number and nature of expected commercial product launches from Nualtis’ product pipeline; the development, regulatory pathway, commercialization and market opportunity for Nualtis’ human and animal health programs; the expectation of and timing to complete additional tranches of the Offering; the conversion, repayment and potential dilution associated with the Debentures; the timing to hold the Meeting to receive the Required Approvals; the Company’s ability to fund the Deferred Payment and maintain sufficient liquidity following completion of the Offering; and the plans, objectives, future outlook and financial position of the Company in general. All forward-looking statements are given pursuant to the “safe harbour” provisions of applicable securities legislation.

The forward-looking statements and financial outlook information contained in this news release are based on a number of material factors, expectations, assumptions and estimates made by the Company in light of its experience and perception of historical trends, current conditions and expected future developments, including, without limitation, assumptions regarding: the successful integration of Nualtis into the Company’s operations; the ability of Nualtis and its partners to continue to perform their respective contractual obligations and maintain existing commercial relationships; the continued validity, enforceability and availability of applicable intellectual property rights; the ability of Nualtis and its partners to successfully complete development activities, clinical studies, analytical work, manufacturing validation and scale-up activities within anticipated timelines; the ability of Nualtis to find commercial partners for products in its pipeline; the timely submission, review and receipt of required regulatory approvals; the absence of material adverse regulatory findings, manufacturing deficiencies, safety concerns, intellectual property disputes or litigation outcomes (including ongoing patent litigation relating to Belbuca^®) that would materially delay or prevent commercialization; the ability of Nualtis’ partners to successfully commercialize, market and distribute products incorporating Nualtis’ technology; expected market acceptance of such products; contractual economics under existing and future partner arrangements being in line with expectations; the availability of sufficient manufacturing capacity; the absence of material launch delays or partner non-performance; the capacity of Nualtis’ partners to fund, market, distribute and commercialize applicable products as expected; the ability of the Company to complete additional tranches of the Offering and otherwise satisfy the Deferred Payment and other funding requirements; the availability of capital on acceptable terms; prevailing economic, market, industry and regulatory conditions; and the continued execution of the Company’s strategic plans.

Actual results may differ materially from those expressed or implied by the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, without limitation: risks associated with the integration of Nualtis; failure to realize anticipated benefits of the acquisition; delays in, or failure to obtain, required regulatory approvals; unsuccessful clinical, development or validation activities; manufacturing, scale-up or supply-chain challenges or the inability to finance any required capex expenditures; the inability of Nualtis or its partners to successfully commercialize products or achieve anticipated market acceptance; adverse intellectual property developments, including litigation outcomes; the failure of current or future partners to perform as expected; delays in, or failure to achieve, anticipated product launches; the inability to enter into, maintain or expand partner or commercialization arrangements on acceptable terms or at all; changes in market conditions, competitive dynamics, pricing, reimbursement or customer demand; the inability to complete additional tranches of the Offering or otherwise obtain sufficient financing; the inability to satisfy the Deferred Payment when due; dilution resulting from the Debentures; general economic, geopolitical, market or industry conditions; and the other risk factors described in the Company’s public disclosure documents filed on SEDAR+.

Certain forward-looking statements contained herein, including estimates regarding anticipated revenue, commercialization timing and potential economic contribution of products in the Nualtis pipeline, may constitute a “financial outlook” within the meaning of applicable securities laws. Such financial outlook is based on the assumptions described above, together with assumptions regarding launch timing, manufacturing capacity, anticipated production volumes, partner commercialization activities, market penetration, pricing, royalty rates and other contractual economics. The financial outlook is provided solely to assist readers in evaluating the potential contribution of the applicable product to Nualtis’ business if commercialization occurs and may not be appropriate for any other purpose. There can be no assurance that the assumptions underlying such financial outlook will prove correct, and actual results may differ materially from those reflected therein. Readers are cautioned that such financial outlook information contained herein should not be used for purposes other than for which it is disclosed.

No securities regulatory authority has either approved or disapproved of the contents of this news release. The Toronto Stock Exchange accepts no responsibility for the adequacy or accuracy of this news release.

Issuer Contact:

Peter H. Puccetti
Chief Executive Officer and Chairman of the Board
ppuccetti@cosciensbio.com

Giuliano La Fratta
Chief Financial Officer
glafratta@cosciensbio.com

Investor Contact:

IR@cosciensbio.com

---

¹ Source: Skyquest Technology. https://www.skyquestt.com/report/oral-thin-films-market.
² Source: American Migraine Foundation. Migraine and Headache Awareness Month 2025. https://americanmigrainefoundation.org/migraine-and-headache-awareness-month-2/
³ Source: Grand View Research. Migraine Drugs Market (2026 – 2033). https://www.grandviewresearch.com/industry-analysis/migraine-drugs-market
⁴ Source: Collegium Pharmaceutical, Inc Corporate press release, [Feb. 26, 2026].